Vertex Pharmaceuticals Incorporated Announces Exercise of Over-Allotment Options by Underwriters of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriters for its concurrent offerings of common stock and convertible senior subordinated notes have exercised in full their over-allotment option to purchase 900,000 shares of common stock at a public offering price of $17.14 per share and their over-allotment option to purchase an additional $37.5 million aggregate principal amount of 4.75% convertible senior subordinated notes due 2013.